Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19

Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19: a randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N353

Enrollment

100

Registered

2020-04-27

Start date

2020-05-14

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Routine care (For outpatients: 250 mg chloroquine tablets every 12 hours for the first day and then every day for up to 6 days

for inpatients: tablet Lupinavir 200 mg and tablet Ritonavir 50 mg every 12 hours for 14 days) plus plasma of patients recovered from covid-19 500 U every week for at least 3 weeks. Intervention 2: Co

for inpatients: tablet Lupinavir 200 mg and tablet Ritonavir 50 mg every 12 hours for 14 days).

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years, Moderate to severe covid-19 disease,

Exclusion criteria

Exclusion criteria: Pregnancy, IGA deficiency

Design outcomes

Primary

Measure	Time frame
Dyspnea. Timepoint: Every day for 3 weeks. Method of measurement: With taking history and physical examination.;Fever. Timepoint: Every day for 3 weeks. Method of measurement: With physical examination.;Cough. Timepoint: Every day for 3 weeks. Method of measurement: With taking history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamereh Ghelichkhani

Hamedan University of Medical Sciences

sa.ghelichkhani@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026